Last edition
News about "Adverse Drug Events (ADEs) "
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer
The US FDA has cleared the OncoMate MSI Dx Analysis System as a companion diagnostic to guide pembrolizumab-based combination therapy in advanced endometrial cancer. The PCR-based assay determines microsatellite instability (MSI) status in tumour tissue, with support from Merck, developer of pembrolizumab and lenvatinib.
Adverse Drug Events (ADEs) | 15/11/2025 | By Dineshwori | 167
Graph Secures USD 3 Million Seed Funding from Bessemer for AI-Driven Drug Safety
California-based Graph AI has announced its USD 3 Million Seed round, led by Bessemer Venture Partners. The investment will enable Graph to accelerate product innovation, expand its engineering team, and drive global market adoption.
Adverse Drug Events (ADEs) | 17/10/2025 | By Dineshwori | 133
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy